On May 29, 2019 MaxCyte reported that Doug Doerfler, Chief Executive Officer, will provide a company overview at the 2019 BIO International Convention on Wednesday, June 5, at 1:15 p.m. ET at the Pennsylvania Convention Center in Philadelphia (Press release, MaxCyte, MAY 29, 2019, View Source [SID1234537619]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In his presentation, Mr. Doerfler will discuss:
The status of MaxCyte’s Phase I dose-escalation clinical trial with MCY-M11, a wholly-owned non-viral mRNA-based therapeutic candidate from MaxCyte’s CARMA platform. Investigators recently began dosing in the trial’s second cohort of individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma. MaxCyte is one of a small number of companies with a cell therapy for solid tumours in the clinic, and successful dosing represents MaxCyte’s unique approach to chimeric antigen receptor ("CAR") therapy, including its rapid manufacturing process.
MaxCyte’s commercial momentum including new multi-drug commercial agreements signed with CRISPR Therapeutics, Precision BioSciences and with Kite, a Gilead Company. All programs enable non-viral cell engineering for development of multiple CAR-T drug candidates. MaxCyte’s total number of cell therapy partnered program licenses total more than 70 including more than 35 partnered program licensed for clinical development.
MaxCyte’s newly launched next generation of commercially-oriented instruments and consumables, under the ExPERT brand. This includes three instrument formats with enhanced design and functionality, coupled with a wider range of consumables that offer expanded utility from early research to clinical and commercial use.
For more information about the conference, please visit: //convention.bio.org/